Bellicum Pharmaceuticals, Inc.
METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION

Last updated:

Abstract:

The technology relates generally to the field of immunology and relates in part to compositions and methods for activating cells, including, for example T cells that express chimeric antigen receptors or recombinant TCRs, and reducing cytotoxicity, using chimeric polypeptides including MyD88 and signaling domains of receptor mediators of costimulation.

Status:
Application
Type:

Utility

Filling date:

8 May 2018

Issue date:

20 May 2021